Clinical Research Directory

Phase I Trial of an Investigational Small Pox Medication

The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

This study is designed to evaluate the immunogenicity profile of JYNNEOS® when 2 doses are administered subcutaneously (SC) 4 weeks apart; and potential immunological interference while concomitantly administering TPOXX or placebo orally twice daily (BID) for 28 days.

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

Safety and PK study in adults weighing more than 120 kg

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

An open-label, drug-drug interaction study with TPOXX and phosphate binders.

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when administered twice daily (BID) for 28 days in adult subjects.

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.

A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox

Phase 4, Observational Field Study in Patients Treated With TPOXX for Smallpox Disease

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.

Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthopox viruses.

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.

A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects